Neuroferritinopathy: update on clinical features and pathogenesis

Area of Science:

• Genetics
• Neurology
• Biochemistry

Background:

• Neuroferritinopathy is an autosomal dominant disorder affecting movement.
• It is caused by mutations in the ferritin light chain gene (FTL).
• Common symptoms include chorea, dystonia, and parkinsonism.

Purpose of the Study:

• To summarize the genetic basis, clinical presentation, and pathological findings of neuroferritinopathy.
• To review current therapeutic approaches and their limitations.

Main Methods:

• Review of existing literature on neuroferritinopathy.
• Analysis of clinical, imaging, and neuropathological data.
• Examination of cellular and animal models.

Main Results:

• FTL gene mutations, particularly 460insA, are the cause.
• Brain MRI reveals basal ganglia iron deposition and cavitation.
• Neuronal loss, ferritin inclusions, increased iron, and oxidative stress are observed.
• Mouse models replicate these abnormalities.

Conclusions:

• No disease-modifying treatments currently exist for neuroferritinopathy.
• Symptomatic treatments include benzodiazepines, botulinum toxin, and tetrabenazine.
• Iron chelation is not effective.